Register for our free email digests:
Latest From Cangene bioPharma Inc.
The race to develop an easier-to-administer and less painful injection of octreotide for acromegaly is getting hotter, as Novartis takes over development of the Swedish company’s novel subcutaneous long-acting octreotide formulation.
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Western Europe
- Parent & Subsidiaries
- ApaTech Ltd.
- Senior Management
Simon Cartmell, CEO
Bruce Powell, CFO
Tom Buckland, PhD, VP, R&D
- Contact Info
Phone: (44) 20 8731 4640
370 Centennial Ave., Centennial Park
Hertfordshire, WD6 3TJ
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.